Assistance for your patients and practice

Most eligible TAGRISSO patients will pay a $0 copay per month

TAGRISSO Patient Savings Program*

Most eligible TAGRISSO patients will pay a $0 copay per month

  • The goal of the TAGRISSO Patient Savings Program is to assist eligible, commercially insured patients with their out-of-pocket costs for TAGRISSO
  • Most eligible patients will pay $0 per month and may have access to up to $26,000 per year to assist with TAGRISSO out-of-pocket costs
  • There are no income requirements to participate in the program

*Patients must meet all eligibility requirements to be enrolled in the program.

or call Access 360 at 1-844-ASK-A360 (1-844-275-2360) for additional information.

Call 1-844-ASK-A360 (1-844-275-2360)
Monday-Friday 8 AM – 8 PM or visit to learn more about the program.

Accessing quality and timely molecular testing

  • Specialty/reference laboratories may now bill Medicare directly for biomarker testing (2019 update to the “14-day rule”)
  • Independent laboratories may now bill Medicare directly for molecular pathology regardless of data collection date
  • The reference or specialty lab performing the test, rather than the hospital that collected the sample, will bill Medicare directly for the testing

TAGRISSO is available for order from the following specialty providers

TAGRISSO is available for purchase from these authorized specialty distributors

Helpful resources for you and your patients

Watch expert discussions to help further educate your patients

TAGRISSO Mechanism of Action Video

TAGRISSO Mechanism of Action
See how TAGRISSO inhibits EGFR mutations, a key driver of disease.
7 min.

Management of Adverse Reactions and Experience With TAGRISSO
Managing patient expectations regarding possible adverse reactions and how to help manage them is a critical aspect of oncology nursing. In this presentation, Beth Sandy, MSN, CRNP, and Blanca Ledezma, MSN, NP, review the most common adverse reactions in the FLAURA study and discuss appropriate symptom management considerations.
11 min 15sec.



No PO Boxes, please. We apologize for any inconvenience.

Reference: TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.


  • There are no contraindications for TAGRISSO
  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
  • Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc >500 msec, and 3.6% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia
  • Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO
  • Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist
  • Postmarketing cases consistent with Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
  • Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
  • Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite


TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Please see complete Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.